BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 8
• 9
• 10
• 11
• 12
• 15
• 16
• 17
• 18
• 19
• 22
• 23
• 24
• 25
• 26
• 29
• 30
• 31

• Press Releases

  Kashiv BioSciences Enters into Exclusive Licensing Agreement with Amneal for Commercialization of a Proposed Biosimilar to XOLAIR® (Omalizumab)

  Kashiv BioSciences, LLC (“Kashiv” or the “Company”) today announced that it has entered into an exclusive licensing agreement for ADL018 with Amneal Pharmaceuticals, Inc.

  July 1, 2024

   · 

  7 min read
• BioMidwest

  Anbio Biotechnology to Showcase at ADLM 2024 with Evolved In Vitro Diagnostic Solutions

  Anbio Biotechnology (“Anbio”), a leading global diagnostic solution provider, is excited to announce its participation in the ADLM 2024 Clinical Lab Expo (formerly the AACC Clinical Lab Expo).

  July 1, 2024

   · 

  1 min read
• Biotech Beach

  GRI Bio to Present at the 8th Annual IPF Summit

  GRI Bio, Inc. today announced that Vipin Kumar Chaturvedi, PhD, Chief Scientific Officer of GRI Bio, will present at the 8th Annual IPF Summit taking place August 20-22, 2024 in Boston, MA.

  July 1, 2024

   · 

  4 min read
• Drug Development

  Artelo Biosciences Presents Preclinical Data on ART26.12 in Breast Cancer-Induced Bone Pain at the 34th Annual International Cannabinoid Research Society Symposium

  Artelo Biosciences, Inc. today announced Professor Saoirse O’Sullivan, Vice President of Translational Sciences at Artelo, presented preclinical data related to ART26.12.

  July 1, 2024

   · 

  5 min read
• Drug Development

  Eirion Therapeutics Announces Initiation of First-in-Human Clinical Trial Evaluating Topical ET-02 for the Treatment of Androgenic Alopecia

  Eirion Therapeutics Inc. announced today that the first participant has been enrolled in a Phase 1 clinical trial to evaluate the safety of the patented topical pharmaceutical ET-02 for the treatment of androgenic alopecia (age-related hair loss).

  July 1, 2024

   · 

  3 min read
• FDA

  Longboard Pharmaceuticals Receives Breakthrough Therapy Designation for Bexicaserin (LP352)

  U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for bexicaserin for the treatment of seizures associated with Developmental and Epileptic Encephalopathies (DEEs).

  July 1, 2024

   · 

  7 min read
• Press Releases

  Radionetics Oncology Enters Into Strategic Agreement With Lilly

  Radionetics Oncology announced today the formation of a strategic relationship with Eli Lilly and Company to take forward Radionetics’ proprietary GPCR targeting small molecule radiopharmaceuticals.

  July 1, 2024

   · 

  2 min read
• Business

  Advanced Bionics Announces New President and Management Board Member

  Advanced Bionics is pleased to announce the appointment of Alistair Simpson as its new president, and Group Vice President (GVP) for cochlear implants on the Sonova Management Board, effective immediately.

  July 1, 2024

   · 

  3 min read
• BioHarvest Sciences Announces Closing of USD $4,329,982 in First Tranche of Private Placement and Conversion of Debt Notes

  BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCD) (FSE: 8MV) (“BioHarvest” or the “Company”) has closed the first tranche of its private placement announced on June 21, 2024.

  July 1, 2024

   · 

  3 min read
• Defence’s AccuTOX Boosts and Synergizes with Immune Checkpoint Inhibitors

  Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) (“Defence” or the “Company”), a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies, is please to announce that Defence’s Accum-002TM (“AccuTOX®") has different mode

  July 1, 2024

   · 

  5 min read